RSV vaccination guidance spans older and younger high-risk adults
Key Questions
What does the updated EULAR 2026 immunization guidance recommend?
EULAR emphasizes day-zero planning and Shingrix vaccination for all patients. It aims to improve protection in rheumatology populations through proactive scheduling.
What evidence exists on Shingrix and dementia risk?
A Wales study found Shingrix reduced dementia risk by 24% in nursing home residents, but an England replication study showed no reduction. Experts call for randomized trials to clarify mixed findings.
How has FDA expanded Abrysvo approval for RSV?
FDA approved Pfizer's Abrysvo for at-risk adults aged 18-59, expanding beyond the prior 60+ indication. NACI also broadened guidance to younger high-risk adults, though ACIP recommendations remain pending.
Current guidance reinforces routine RSV vaccination for adults 75+ and vaccination for adults 60–74 at increased risk. FDA approvals expand risk-based options for younger high-risk adults, including Abrysvo for ages 18–59 and Arexvy for qualifying adults 18–49; payer coverage and broader recommendations remain unsettled. A study finding approximately 9% lower Arexvy antibody titers with same-day administration has uncertain clinical significance and does not currently overturn coadministration practice.